ERBB2 and ductal breast carcinoma in situ: When adjuvant therapy is not randomly allocated, HER2-positive DCIS are much more likely to be irradiated, since these lesions more frequently present with unfavorable histopathological characteristics, such as high nuclear grade, large size, and necrosis [7, 21, 22, 35].